U.S. life sciences real estate faces turbulence in 2025 due to business uncertainty and a drop in demand. However, with 15 major pharmaceutical firms announcing over $270 billion in U.S. biomanufacturing and R&D investments over the next five to 10 years, a boom may be on the horizon. Despite a reset in lab production, diminishing inventory and persistent economic uncertainties, innovative strategies are expected to emerge for lab and biomanufacturing spaces to enhance flexibility and efficiency.
New Phantom Stealer Campaign Hits Windows Machines Through ISO Mounting
Researchers have uncovered a sophisticated phishing campaign originating in Russia that deploys the Phantom information-stealing malware via malicious ISO files. The attack, dubbed “Operation MoneyMount-ISO,”
